0
     

Report Added
Report already added
North America Anticoagulant Reversal Drug Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product (Prothrombin Complex Concentrates, Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, and AndeXXa); End User (Hospital Pharmacies, Retail Pharmacies, and Others)

North America Anticoagulant Reversal Drug Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product (Prothrombin Complex Concentrates, Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, and AndeXXa); End User (Hospital Pharmacies, Retail Pharmacies, and Others)

The anticoagulant reversal drug market in North America is expected to grow from US$ 414.7 million in 2019 to US$ 1,037.9 million by 2027; it is estimated to grow at a CAGR of 12.8% from 2019 to 2027. Anticoagulant reversal drugs are used in the management of hemorrhagic stroke to lower bleeding and allow tissues to recover. As per the CDC, in 2018, 1 in every 6 deaths in the US from cardiovascular disease was due to stroke. It also mentioned that 1 person every 40 seconds suffers from stroke, while the condition causes one death in every 4 minutes. Such high prevalence of stroke boosts the demand for anticoagulant reversal drugs. The rise in prevalence of atrial fibrillation (AFib) is among the other factors bolstering the demand.

Based on product, the North America anticoagulant reversal drugs market is segmented into prothrombin complex concentrates, vitamin K, AndeXXa, protamine, idarucizumab, and tranexamic acid. In 2019, the vitamin K segment accounted for the largest market share. It is a reliable and fast alternative to fresh frozen plasma to control excessive bleeding as it has properties to reverse the effects of oral anticoagulant treatments, which contributes to the wide acceptance for this product. On the other hand, the market for AndeXXa is expected to grow at the fastest CAGR during the forecast period.

In North America, the COVID-19 pandemic has profoundly affected the US, as the country has marked the highest number of positive patients. In 2020, various healthcare research centers shifted their focus solely on the research related to COVID-19 therapeutics. In January 2021, the FDA reached more than 180 drug companies to remind them about the legal requirements for notifying the FDA regarding any anticipated supply disruptions. It also asked them to evaluate their entire supply chain, including the supply of active pharmaceutical ingredients and other components manufactured in China. The FDA has identified ~20 prescription drugs that are the only source of their active ingredients and/or finished drugs from China; however, these drugs are not considered critical drugs. At present, none of the notified companies have reported a shortage. As the crisis moves forward due to lockdown and supply chain disruptions that have affected the sales and manufacturing of anticoagulant reversal drugs for a short period, overall prospects for market growth are considered to be positive.

The North America anticoagulant reversal drug market size has been derived using both primary and secondary sources. To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market. The process also serves the purpose of obtaining overview and forecast for the North America anticoagulant reversal drug market with respect to all the segments pertaining to the region. Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data, as well as to gain more analytical insights into the topic. The participants typically involved in this process include industry expert such as VPs, business development managers, market intelligence managers, and national sales managers—along with external consultants such as valuation experts, research analysts, and key opinion leaders—specializing in the North America anticoagulant reversal drug market. Boehringer Ingelheim International GmbH, Pfizer Inc, Octapharma AG, AMAG PHARMACEUTICALS, INC., Fresenius Kabi AG, Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals), CSL Limited, and Grifols, S.A. are among the players operating in the market in this region.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Anticoagulant Reversal Drug Market – By Product
1.3.2 Anticoagulant Reversal Drug Market – By Distribution Channel
1.3.3 North America Anticoagulant Reversal Drug Market – By Country
2. North America Anticoagulant Reversal Drug Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Anticoagulant Reversal Drug Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Anticoagulant Reversal Drug Market- North America PEST Analysis
4.3 Expert Opinion
5. North America Anticoagulant Reversal Drug Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rise in Prevalence of Atrial Fibrillation (AFib)
5.1.2 Increase in Prevalence of Stroke
5.2 Market Restraints
5.2.1 High Cost of Anticoagulant Reversal Drugs
5.3 Market Opportunities
5.3.1 Increasing Research Activities on Anticoagulant Reversal Drugs
5.4 Future Trends
5.4.1 Development and Launch of Innovative Products
5.5 Impact Analysis
6. Anticoagulant Reversal Drug Market – North America Analysis
6.1 North America Anticoagulant Reversal Drug Market Revenue Forecasts and Analysis
7. North America Anticoagulant Reversal Drug Market Analysis and Forecasts To 2027 – By Product
7.1 Overview
7.2 Anticoagulant Reversal Drugs Market Share, by Product, 2019 and 2027 (%)
7.3 Prothrombin Complex Concentrates
7.3.1 Overview
7.3.2 Prothrombin Complex Concentrates: Anticoagulant Reversal Drugs Market– Revenue and Forecast to 2027 (USD Million)
7.4 Vitamin K
7.4.1 Overview
7.4.2 Vitamin K: Anticoagulant Reversal Drugs Market– Revenue and Forecast to 2027 (USD Million)
7.5 Protamine
7.5.1 Overview
7.5.2 Protamine: Anticoagulant Reversal Drugs Market– Revenue and Forecast to 2027 (USD Million)
7.6 Tranexamic Acid
7.6.1 Overview
7.6.2 Tranexamic Acid: Anticoagulant Reversal Drugs Market– Revenue and Forecast to 2027 (USD Million)
7.7 Idarucizumab
7.7.1 Overview
7.7.2 Idarucizumab: Anticoagulant Reversal Drugs Market– Revenue and Forecast to 2027 (USD Million)
7.8 Andexxa
7.8.1 Overview
7.8.2 Andexxa: Anticoagulant Reversal Drugs Market– Revenue and Forecast to 2027 (USD Million)
8. North America Anticoagulant Reversal Drug Market Analysis and Forecasts to 2027– By Distribution Channel
8.1 Overview
8.2 Anticoagulant Reversal Drugs Market Share, by Distribution Channel, 2019 and 2027 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: Anticoagulant Reversal Drugs Market– Revenue and Forecast to 2027 (USD Million)
8.4 Retail Pharmacies
8.4.1 Overview
8.4.2 Retail Pharmacies: Anticoagulant Reversal Drugs Market– Revenue and Forecast to 2027 (USD Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Anticoagulant Reversal Drugs Market– Revenue and Forecast to 2027 (USD Million)
9. Anticoagulant Reversal Drug Market Revenue and Forecasts to 2027 – Geographical Analysis
9.1 North America: Anticoagulant Reversal Drugs Market
9.1.1 Overview
9.1.2 North America: Anticoagulant Reversal Drugs Market, by Country, 2019 & 2027 (%)
9.1.3 US: Anticoagulant Reversal Drugs Market – Revenue and Forecast to 2027 (USD Million)
9.1.3.1 US: Anticoagulant Reversal Drugs Market – Revenue and Forecast to 2027 (USD Million)
9.1.3.2 US: Anticoagulant Reversal Drugs Market, by Product, 2018–2027 (USD Million)
9.1.3.3 US: Anticoagulant Reversal Drugs Market, by Distribution Channel 2018–2027 (USD Million)
9.1.4 Canada: Anticoagulant Reversal Drugs Market – Revenue and Forecast to 2027 (USD Million)
9.1.4.1 Canada: Anticoagulant Reversal Drugs Market – Revenue and Forecast to 2027 (USD Million)
9.1.4.2 Canada: Anticoagulant Reversal Drugs Market, by Product, 2018–2027 (USD Million)
9.1.4.3 Canada: Anticoagulant Reversal Drugs Market, by Distribution Channel 2018–2027 (USD Million)
9.1.5 Mexico: Anticoagulant Reversal Drugs Market – Revenue and Forecast to 2027 (USD Million)
9.1.5.1 Mexico: Anticoagulant Reversal Drugs Market – Revenue and Forecast to 2027 (USD Million)
9.1.5.2 Mexico: Anticoagulant Reversal Drugs Market, by Product, 2018–2027 (USD Million)
9.1.5.3 Mexico: Anticoagulant Reversal Drugs Market, by Distribution Channel 2018–2027 (USD Million)
10. Impact Of COVID-19 Pandemic on North America Anticoagulant Reversal Drug Market
10.1 North America: Impact Assessment of COVID-19 Pandemic
11. Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.2.2 Organic Developments Done By Companies
11.3 Inorganic Developments
11.3.1 Overview
11.3.2 Inorganic Developments Done By Companies
Source: The Insight Partners Analysis, Website, Press Releases and Others
12. COMPANY PROFILES
12.1 Boehringer Ingelheim International GmbH
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Pfizer Inc.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Octapharma AG
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 AMAG PHARMACEUTICALS, INC.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Fresenius Kabi AG
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 CSL Limited
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Grifols, S.A.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
13. Appendix
13.1 About the Insight Partners
13.2 Glossary of Terms

Table 1. US Anticoagulant Reversal Drugs Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 2. US Anticoagulant Reversal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 3. Canada Anticoagulant Reversal Drugs Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 4. Canada Anticoagulant Reversal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 5. Mexico Anticoagulant Reversal Drugs Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 6. Mexico Anticoagulant Reversal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 7. Glossary of Terms, Anticoagulant Reversal Drug Market

Figure 1. Anticoagulant Reversal Drug Market Segmentation
Figure 2. North America Anticoagulant Reversal Drug Market Overview
Figure 3. Vitamin K Segment Held Largest Share of Product in Anticoagulant Reversal Drug Market
Figure 4. Hospital Pharmacies Segment Held Largest Share of Distribution Channel in Anticoagulant Reversal Drug Market
Figure 5. US is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Anticoagulant Reversal Drug Market - North America PEST Analysis
Figure 7. Anticoagulant Reversal Drug Market Impact Analysis of Driver and Restraints
Figure 8. North America Anticoagulant Reversal Drug Market – Revenue Forecasts and Analysis – 2019- 2027
Figure 1. Anticoagulant Reversal Drugs Market Share, by Product, 2019 and 2027 (%)
Figure 2. Prothrombin Complex Concentrates: Anticoagulant Reversal Drugs Market– Revenue and Forecast to 2027 (USD Million)
Figure 3. Vitamin K: Anticoagulant Reversal Drugs Market– Revenue and Forecast to 2027 (USD Million)
Figure 4. Protamine: Anticoagulant Reversal Drugs Market– Revenue and Forecast to 2027 (USD Million)
Figure 5. Tranexamic Acid: Anticoagulant Reversal Drugs Market– Revenue and Forecast to 2027 (USD Million)
Figure 6. Idarucizumab: Anticoagulant Reversal Drugs Market– Revenue and Forecast to 2027 (USD Million)
Figure 7. Andexxa: Anticoagulant Reversal Drugs Market– Revenue and Forecast to 2027 (USD Million)
Figure 8. Anticoagulant Reversal Drugs Market Share, by Distribution Channel, 2019 and 2027 (%)
Figure 9. Hospital Pharmacies: Anticoagulant Reversal Drugs Market– Revenue and Forecast to 2027 (USD Million)
Figure 10. Retail Pharmacies: Anticoagulant Reversal Drugs Market– Revenue and Forecast to 2027 (USD Million)
Figure 11. Others: Anticoagulant Reversal Drugs Market– Revenue and Forecast to 2027 (USD Million)
Figure 12. North America: Anticoagulant Reversal Drugs Market, by Key Country – Revenue (2019) (USD Million)
Figure 13. North America: Anticoagulant Reversal Drugs Market, by Country, 2019 & 2027 (%)
Figure 14. US: Anticoagulant Reversal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 15. Canada: Anticoagulant Reversal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 16. Mexico: Anticoagulant Reversal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 17. Impact of COVID-19 Pandemic in North American Country Markets
Figure 18. Growth Strategies Done by the Companies in the Market, (%)

Report Title: North America Anticoagulant Reversal Drug Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product (Prothrombin Complex Concentrates, Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, and AndeXXa); End User (Hospital Pharmacies, Retail Pharmacies, and Others)


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

2022 What's Next for Vietnam Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for Vietnam Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for Venezuela Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for Venezuela Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for US Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for US Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for Uruguay Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for Uruguay Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for United Arab Emirates Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for United Arab Emirates Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for Ukraine Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for Ukraine Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM